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An important role for the mammalian body is to guard against infection by pathogenic
micro-organisms. There are five main classes of pathogens, namely, viruses, bacteria,
parasites, fungi, and worms. The complex relationships between these pathogenic mi-
cro-organisms and the vertebrate host are perhaps most clearly understood for viruses.
The survival of viruses depends on the survival of susceptible hosts. In recent years,
chemokines have been shown to play an integral role in the recruitment of cells to sites
of infection, thus mediating the healing process. This review will provide an overview of
immune responses with reference to viral infections and chemokines.
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Introduction
A variety of factors, genetic and immunological,
can influence the susceptibility of a host to viral in-
fection. The immune system is composed of innate
and adaptive components. Innate components in-
clude natural killer (NK) cells, mononuclear
phagocytes (macrophages and blood monocytes),
complements, and some cytokines. These form the
first line of defense. Activation of the host immune
system occurs as a result of invasion by microbes.
This activation is of paramount importance for the
elimination of foreign invaders. Innate immunity is
the nonspecific arm of the immune system and
comprises noninducible and inducible responses.
Innate responses that are noninducible occur im-
mediately after infection and are mediated mainly
by unactivated NK cells.1 Inducible responses also
occur early after infection and are triggered by viral
infections usually via the induction of interferons
(IFNs).1 Activated NK cells, mononuclear phago-
cytes, polymorphonuclear cells (PMNs), IFNs, and
tumor necrosis factor (TNF), as well as the alterna-
tive complement pathway, constitute the immedi-
ate-early innate and inducible, but antigen nonspe-
cific, antiviral pathways.2
Adaptive responses are elicited later and represent
the more advanced arm of the immune response.
They consist of B and T lymphocytes that are acti-
vated in a specific manner by antigens, resulting in
their clonal expansion. This leads to triggering of
effector mechanisms, such as the secretion of anti-
gen-specific antibodies by B lymphocytes, and the
production of cytolytic effector molecules and cy-
tokines with antiviral and immunomodulatory
properties by T lymphocytes. The activation of
these responses also leads to the generation of im-
munological memory to specific antigens.
This review attempts to describe the various facets
of the host immune responses in the context of a vi-
ral infection and the involvement of chemokines in
these responses.
Innate Immunity
Natural Killer Cells
NK cells are large, granular leukocytes and ac-
count for up to 15% of human blood lymphocytes.
These cells mediate lysis of tumor and virus-infect-
ed target cells in a nonmajor histocompatability
complex (MHC)-restricted fashion.3 The absence
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of B and T lymphocyte antigen receptors on NK
cells distinguishes these cells from other lymphoid
cells. NK cells usually carry Fc receptors and can be
characterized by a number of cell markers. Murine
NK cells are CD3-, CD2+, CD16+, asialoGM1
+ and
NK1.1+.4,5
NK cells are activated early after a virus infection,
and this activation is due partly to the production
of IFNs α and β.6,7 Interleukin (IL)-2 and IL-12 are
also important factors in the activation of NK
cells.8-10 The importance of NK cells in antiviral im-
munity have been demonstrated in a number of vi-
ral infections, such as vaccinia virus (VV),11,12
murine cytomegalovirus (MCMV),13 human
CMV,14 and herpes simplex virus (HSV).15 In-
traperitoneally inoculated adult mice depleted of
NK cells with antisera to asialoGM1 or with mon-
oclonal antibody (mAb) to the NK1.1 alloantigen
showed enhanced virus growth in organs following
infection with VV,11,12 MCMV,16 murine hepatitis
virus (MHV),11 influenza virus,17 and ectromelia
virus (EV).18 Antiviral effects of NK cells are medi-
ated through direct lytic activity of virus-infected
cells, through antibody-dependent cell-mediated
cytotoxicity3 and by the production of antiviral cy-
tokines such as IFN-γ or TNF.19,20 Studies conduct-
ed at early times after lymphocytic choriomeningi-
tis virus (LCMV) or MCMV infection
demonstrate that NK cells express high levels of
IFN-γ mRNA in murine spleen compartments.21
Recent studies have implicated a number of
chemokines (see section “Factors Involved in the
Immune Response to Virus Infections”) in the re-
cruitment and activation of NK cells. CC and CXC
chemokines (refer to Table 2 for new nomenclature
for chemokine system) can induce NK cell migra-
tion in vitro,22 whereas several CC chemokines have
been shown to augment NK-specific cytolytic re-
sponses in a dose-dependent fashion.22 The IFN-in-
ducible protein-10 (IP-10) and lymphotactin can
induce the chemotaxis and calcium mobilization in
CC chemokine-activated killer cells.23 The presence
of chemokine receptors specific for MCP-1 (mono-
cyte chemotactic protein),24 IP-10, and human Mig
(monokine induced by IFN-γ) on IL-2-activated
NK cell clones is consistent with a role for the cor-
responding chemokines in NK cell recruitment. It
has been demonstrated that MCMV infection in-
duces liver NK cell inflammation and protection
through MIP-1 (macrophage inflammatory pro-
tein)-dependent pathways.26 INSERT REF NO. 25
BETWEEN 24 AND 26Activated NK cells may
be an important source of CC chemokines in hu-
man immunodeficiency virus type 1 (HIV-1)-in-
fected individuals and may suppress HIV-1 replica-
tion by CC chemokine-mediated mechanisms, in
addition to classic NK-mediated lytic mecha-
nisms.27
Macrophages/Monocytes
Macrophages and blood monocytes are bone mar-
row–derived mononuclear phagocytic cells. These
cells play a major role as antiviral effectors of both
the innate and adaptive immune responses.
There are several ways in which macrophages
promote the generation of antiviral immune re-
sponses. Production of cytokines, such as IFN-α
and IL-12 by macrophages, enhances NK cell cyto-
toxicity and cytokine production and promotes
generation of a cell-mediated immune (CMI) re-
sponse.28,29 Phagocytosed extracellular antigens pre-
sented by macrophages to CD4+ T lymphocytes in
association with MHC class II molecules can initi-
ate antiviral immune responses. Macrophage ex-
pression of MHC class II molecules is up-regulated
following activation with IFN-γ, which in turn may
increase antigen presentation to CD4+ T lympho-
cytes.30 Macrophages can also be induced to express
other cell surface molecules that are important in
antigen presentation such as B7, ICAM-1 (intercel-
lular adhesion molecule) and LFA-3 (lymphocyte
function-associated antigen).31-33 IFN-γ-activated
macrophages can restrict replication of HSV-1, VV,
and EV, and this is mediated substantially through
the induction of iNOS (inducible nitric oxide syn-
thase).34,35 However, production of high levels of ni-
tric oxide (NO) by macrophages can suppress T
lymphocyte proliferation and antibody produc-
tion.36,37 Activated macrophages are also able to re-
strict virus replication in contiguous virus-infected
epithelial or fibroblast cells in an NO-dependent
fashion.38
Macrophages can be induced to produce
chemokines such as Mig, Crg-2 (cytokine respon-
sive gene), murine homologue to human IP-10,
MCP-1, MDC (macrophage-derived chemokine),
ABBREVIATIONS
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HIV Human immunodeficiency 
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ICAM Intercellular adhesion 
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IFN Interferon
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and MRP-2 (macrophage inflammatory protein-re-
lated protein).39-43 Thus, macrophages can also in-
fluence the outcome of an infection through re-
cruitment of leukocytes. For instance, infection of
human monocytes with influenza A virus results in
a rapid expression of the mononuclear cell attract-
ing CC chemokines.44 Additionally, the T lympho-
cyte and NK cell chemoattractants MuMig
(murine Mig) and Crg-2 are expressed in CD11b+
cells, presumably macrophages, at the margin be-
tween the red and white pulps in the spleen after
Toxoplasma gondii infection.45 Chemokines are also
produced by macrophages infected with Listeria
monocytogenes, and their release is differentially reg-
ulated by different cytokines.46 Neutralizing anti-
body studies have implicated MCP-1 as a major
mediator of macrophage recruitment in several in-
flammatory models.47 In MCP-1 transgenic mice,
monocytes/macrophages are recruited to sites of
MCP-1 expression.48,49 In addition, mice deficient
in MCP-1 or the receptor for MCP-1 (CCR2) were
unable to recruit monocytes/macrophages 72 h af-
ter intraperitoneal administration of thioglycol-
late.50 Other than MCP-1, CC chemokines, such as
MIP-1α and MIP-1β, have also been shown to be
potent monocyte chemoattractants.51 In HIV-1 in-
fection, it has been found that macrophage-tropic
strains of this lentivirus utilize the chemokine re-
ceptor CCR5 for entry and fusion and that the
natural ligands MIP-1α, MIP-1β, and RANTES
(Regulated on Activation, Normal T cell Ex-
pressed and Secreted) inhibit viral entry (see sec-
tion “Factors Involved in the Immune Response to
Virus Infections”).
Polymorphonuclear Cells
PMN cells are regarded primarily as a major com-
ponent in natural immunity to bacteria. However,
some evidence suggests that they may play an im-
portant role in the early nonspecific defense against
viral infections. For instance, HSV-2 virions were
found to be phagocytosed in vesicular lesions of pe-
nile skin.52 In a study using influenza virus, it was
found that PMN-like cells were important for ear-
ly protection of mice.53 In vitro studies have shown
that PMNs are antiviral for VV, and this virucidal
action is believed to be related to the induction of
oxidative metabolism.54 The most definitive evidence
comes from studies with the mouse pathogen, EV.
Acute depletion of neutrophils with specific mAb
transformed the normally benign infection in ge-
netically resistant C57BL/6 mice to fulminant dis-
ease with 100% mortality (Dr G. Karupiah, JC-
SMR, personal communicationPROVIDE
MONTH AND YEAR). PMNs can also be in-
duced to produce NO, which also has antiviral
properties.55 Production of TNF and IFNs during
viral infections has been shown to augment the
phagocytic activities of PMN.56
IL-8, a product of virus-infected fibroblasts, is a
chemokine and granule release stimulus for PMN
and may mediate some of the immunomodulatory
effects of TNF observed on these cells.57 It was re-
cently demonstrated that exposure of neutrophils
to various microbial pathogens led to an increase in
IL-8 and MIP-1α, suggesting the importance of
neutrophils in the regulation of inflammation and
the control of infection.58,59 In MIP-2 (macrophage
inflammatory protein) transgenic mice, it has been
demonstrated that neutrophils are recruited to sites
of MIP-2 expression.60 Evidence also suggests that
many or all of the ELR-CXC (glutamic acid-
leucine-arginine-CXC) chemokines such as NAP-2
(neutrophil-activating-peptide) and ENA-78 (ep-
ithelial-derived neutrophil attractant) have neu-
trophil attractant capacity, possibly mediated
through interaction with a shared CXC chemokine
receptor, the so-called IL-8 receptor B now known
as CXCR2.61 In IL-8 receptor homologue gene
knockout (GKO) mice, human IL-8 was unable to
chemoattract neutrophils.62 These mice demon-
strate a paradoxical response to acute and chronic
infection with Listeria monocytogenes.63 Overexpres-
sion of IL-8 in IL-8 transgenic mice demonstrated
a decrease in L-selectin expression on the neu-
trophil surface and impaired thioglycollate-mediat-
ed neutrophil extravasation.64
Adaptive Immunity
Antigen Presentation and T-Lymphocyte Activation
T lymphocytes recognize antigens (peptides) in
association with host MHC molecules on antigen-
presenting cells (APCs).65 Antigen recognition by T
lymphocytes is mediated via a T-cell surface het-
erodimer receptor (TCR).66
REVIEWS
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Two classes of MHC molecules exist, which differ
in structure, composition, and the nature of the
peptide they bind.67 The MHC class I-restricted
CD8+ CTL (cytotoxic T lymphocyte) recognize
antigenic peptides synthesized within target
cells.68,69 These antigens are degraded in the cytosol
by proteosomes, and the resulting peptide frag-
ments are translocated to the endoplasmic reticu-
lum (ER) by TAP (transporter associated with anti-
gen processing) molecules where the MHC
molecules are present.70,71 The peptides then bind to
the class I MHC molecules and are ultimately
transported to the cell surface. On the other hand,
class II MHC-restricted CD4+ helper T (Th) lym-
phocytes recognize peptides derived exogenously.72
Upon binding of degraded peptides to the MHC
class II molecules in the ER, the complex is then
presented on the cell surface.67
Interaction between the TCR and peptide-MHC
molecules, although essential, is insufficient to ini-
tiate activation of T lymphocytes.73 A range of ac-
cessory molecules are required for costimulatory in-
teractions between T lymphocytes and APC,
including ICAM-1,74 LFA-3,75 and VCAM-1 (vas-
cular cell adhesion molecule).74-76 Additionally, B7-
1 (CD 80), B7-2 (CD 86), or B7-3 on APC and
CD28 on T lymphocytes have also been shown to
be vital for T lymphocyte activation.77 Interaction
of CD28 with B7-1/B7-2 results in cell cycle pro-
gression and IL-2 production.78 More recently,
TCR and CD28 ligation have been shown to play
an important role in the regulation of chemokine
gene expression in T lymphocytes.79,80 The require-
ment for T lymphocyte activation may vary among
T lymphocyte subsets.81
Cytotoxic T Lymphocytes (CTLs)
The role of CD8+, MHC-class I restricted cyto-
toxic T lymphocytes (CTLs), is important in the re-
covery from primary virus infection. CTL antiviral
responses are at their peak following infection by
EV, LCMV, HSV, or influenza virus.82-85 The ability
of CTLs to mediate recovery from poxvirus infec-
tion in vivo has been demonstrated by adoptive
transfer experiments.86,87
CTL activity has usually been linked to class I
MHC-restricted cytotoxicity. However, class II
MHC-restricted CD4+ CTL have also been de-
scribed against LCMV, influenza virus, vesicular
stomatitis virus (VSV), and MHV.88-91
Cytolytic activity of CTLs is mediated through
perforin or through interactions with Fas antigen
via calcium (Ca)-dependent or Ca-independent
mannerCORRECT WORD CHOICE?, respec-
tively.92 Results obtained from perforin GKO mice
provide strong evidence that perforin-mediated cy-
totoxicity is important in the control of some virus
infections such as LCMV,93 EV (Dr. G. Karupiah,
JCSMR, personal communicationPROVIDE
MONTH AND YEAR) but not VV.94 Calcium-in-
dependent cytotoxicity is mediated through the
binding of Fas molecule on target cells with its lig-
and (FasL) found on activated T lymphocytes,
which result in apoptosis.95
Studies have shown that CD8+ T lymphocytes can
secrete a wide range of cytokines, including IFN-γ,
IL-2, IL-3, TNF, and GM-CSF. There is some evi-
dence to suggest that IFN-γ is involved in the an-
tiviral action of CD8+ CTL.87
Based on the findings described above, it has been
proposed that cytokines are important in the con-
trol of cytopathic viruses (e.g., VV), whereas cyto-
toxicity is critical in the control of infection with
noncytopathic viruses (e.g., LCMV).96 However,
findings made with EV, a cytopathic virus closely
related to VV, question the simplicity of this propo-
sition. Recovery from EV clearly requires the par-
ticipation of perforin-dependent cytotoxicity and
cytokine (IFN-γ) producing T lymphocytes.97
While lytic activity is regarded as an important
component of CD8+ T lymphocyte-mediated HIV-
1 suppression, cell-free supernatants from cultures
of activated CD8+ T lymphocytes are able to dra-
matically inhibit HIV-1 infection and fusion in
both T lymphocytes and macrophages. The elusive
CD8+ cell-derived HIV-suppressive factors were
identified by Cocchi and colleagues who attributed
the HIV-inhibitory activity of CD8+ T lymphocyte
to the combined actions of the CC chemokines
MIP-1α, MIP-1β, and RANTES.98 Furthermore, it
was shown that these CC chemokines, together with
granzyme A, are localized in the cytolytic granules
of HIV-1-specific CD8+ CTLs, and their secretion
together facilitates lysis of virion-producing cells
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and inhibition of free virus.99 In addition, a recent
report showed that one mechanism for the induc-
tion of HIV-1-specific cytotoxicity was mediated
by RANTES via the chemokine receptor CCR3.100
Helper T Lymphocytes (CD4+)
CD4+ T lymphocytes are activated during virus
infections and can therefore influence the immune
response to infection. This is regulated through
their effect on antibody production, CTL, and
macrophage activity, as well as production of an-
tiviral cytokines.101
Varying results have been reported on the role of
CD4+ T lymphocyte in induction of antiviral CTL
responses. For instance, CD4+ T lymphocyte deple-
tion studies in vivo indicate that help is important
for induction of CTL responses to Moloney Sarco-
ma virus (MSV), LCMV, and EV.102-104 On the oth-
er hand, other studies suggest that this may not be
the case as demonstrated by similar depletion stud-
ies in vivo during EV and VV and LCMV infec-
tions.105,106 The reasons for these differences are not
clear but may be related to depletion protocols and
the virus strain used.
CD4+ T lymphocytes are also able to mediate an-
tiviral activity through induction and secretion of
antiviral cytokines, such as IFN-γ. CD4+ T lym-
phocytes may also have direct antiviral cytotoxic ef-
fects, as is the case against influenza virus–infected
cells.107 Early during the course of virus infections,
IgM antibody can be produced in the absence of
CD4+ T lymphocytes, but this cell population is
critical for inducing a switch from IgM to IgG pro-
duction in B lymphocytes.108,109
Th1 and Th2 Paradigm
The Th1/Th2 paradigm has dominated the inter-
pretation of data obtained from in vitro and in vivo
studies on T lymphocyte cytokine production.
More than 10 years ago, Mosmann and Coffman
first reported that long-term lines of murine CD4+
T lymphocytes could be grouped into 2 subsets,
which they termed T helper type 1 (Th1) and T
helper type 2 (Th2), based on their distinctive cy-
tokine production patterns.110 Their activities have
been correlated to types of cytokines secreted by Th
lymphocytes. Th1 clones produce cytokines such as
IFN-γ, IL-2 and these are associated with cell-me-
diated immunity, whereas Th2 clones produce cy-
tokines associated with humoral immunity, for ex-
ample, IL-4, IL-5, and IL-10.110,111 Many T
lymphocyte clones cannot be classified as either
Th1 or Th2, as they produce both Th1 and Th2 cy-
tokines, and these cells are described as Th0 lym-
phocytes.112,113 It has been proposed that during a
polarized Th1 or Th2 response, the spectrum of cy-
tokine production of the T lymphocyte population
is skewed toward Th1 or Th2.114
It is now clear that these patterns of cytokine pro-
duction are not restricted to CD4+ T lymphocytes,
because NK cells and CD8+ T lymphocytes can
also produce Th1 and Th2 cytokines. Hence, a
more appropriate terminology for the 2 profiles of
cytokine production and the response generated is
type 1 (T1) and type 2 (T2).115
Factors that favor the development of Th1 or Th2
lymphocytes include antigen concentration, the
type of APC and accessory molecule that is ex-
pressed by the APC, and the type of cytokines pres-
ent during initial priming of T lymphocytes.116-119
The latter is believed to be the most important fac-
tor. For instance, IL-4 results in the development of
Th2 lymphocytes, whereas IL-12 presence tends to
favor the development of Th1 lymphocytes.118,119
Both cytokines can inhibit the development of the
alternative response.
In addition to effector function, activated T lym-
phocytes also acquire different migratory capacities,
and this is critical to efficient regulation of the im-
mune response. The regulation of leukocyte migra-
tion is an intricate process involving the participa-
tion of adhesion molecules such as ICAM-1,
ICAM-2, ICAM-3, VCAM-1, selectins, and inte-
grins, as well as chemokines and chemokine recep-
tors.120-122 Austrup and colleagues showed that P-
and E-selectin mediate recruitment of Th1, but not
Th2, lymphocytes into inflamed tissues.123 Recent-
ly, it was reported that human Th1 and Th2 lym-
phocyte lines differentially express chemokine re-
ceptors and, accordingly, differentially migrate in
response to different chemokines.124,125 These stud-
ies indicate that chemokines are part of effector and
amplification mechanisms of polarized Th1- and
Th2-mediated immune responses, and their recep-
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tors might serve as Th1 (T1) versus Th2 (T2)
markers.
B Lymphocytes and the 
Humoral Immune Response
B lymphocyte-antigen recognition is mediated by
membrane immunoglobulin antigen receptors,
which mediates the internalization of antigen,
which is then degraded and presented in associa-
tion with class II MHC molecules. For the produc-
tion of antibody, B lymphocytes require stimulato-
ry signals from activated CD4+ T lymphocytes.
Antibodies are important in preventing reinfec-
tion with many viruses.126 Antibody-mediated
mechanisms that are thought to control virus infec-
tions are the neutralization of virus particles and
the cytolysis of antibody-coated infected cells. Al-
though an antibody has little role in the recovery of
a primary viral infection, it is important in the re-
covery from some viral infections like Sindbis virus,
VSV, and EV.97,127-129 Viruses producing systemic
disease characterized by a plasma viremia appear to
be controlled principally by circulating antibody.
The killing of virus-infected cells can also be me-
diated by the binding of a complement to an anti-
body on virus-infected cells. This triggers the clas-
sical pathway of complement-mediated
cytotoxicity. Several studies have demonstrated that
complement-mediated lysis may be important in
the control of virus infections such as LCMV.130
The importance of complement in virus infection
is also reflected by the ability of some viruses to
block the complement pathway.131
There is little information on chemokine activi-
ties and chemokine receptor expression on B lym-
phocytes. Two newly identified CC chemokine re-
ceptors, CCR6 and CCR7, were reported to be
present on T and B lymphocytes, but no ligand was
found that induces chemotaxis of B lympho-
cytes.132,133 A CXC chemokine, SDF-1 (stromal cell-
derived factor), that was originally described as a
growth factor for progenitor B lymphocytes, is
chemotactic for pre- and pro-B lymphocyte cell
lines, but it does not attract mature B lympho-
cytes.134 Another study showed that IL-8 and IP-10
induced a significant chemokinetic response of hu-
man B lymphocytes.135 Recently, it was demonstrat-
ed that BCA-1 (B cell-attracting chemokine), a
CXC chemokine expressed in lymphoid tissues, se-
lectively attracts B lymphocytes via the chemokine
receptor CXCR5.136 With respect to regulation of
antibody production, it was found that IL-8 selec-
tively inhibited IgE and IgG4 production induced
by IL-4, whereas RANTES and MIP-1α selectively
enhanced production of these classes of antibod-
ies.137 More recently, a novel CC chemokine pro-
duced by activated murine B lymphocytes and that
acts selectively on activated T lymphocytes has been
identified.138
Factors Involved in the Immune 
Response to Virus Infections
Interferons (IFNs)
There are 3 distinct species in the IFN family:
IFN-α, IFN-β (classified as type I IFN), and IFN-
γ (classified as type II IFN). The IFNs are inhibito-
ry against a number of DNA and RNA viruses.
They mediate their antiviral effect through synergy
with each other, as well as with the TNFs.
The antiviral activity of IFNs, the property that
led to their discovery nearly 50 years ago, is medi-
ated by a number of intracellular antiviral pathways
that are activated by IFNs.139 IFNs are able to in-
duce antiviral mechanisms through the synthesis of
a number of proteins that inhibit viral infection by
interfering with the regulation of viral and cellular
macromolecular synthesis and degradation (Table
1). In the presence of double-stranded RNA, 2,5
oligoadenylate synthetase, which is induced by
IFN-α, -β, and -γ, activates a ribonuclease that de-
grades host and virus RNA.140 The Mx protein,
which is localized in the nucleus, blocks the repli-
cation of influenza virus in cultured cells as well as
in mice without affecting the replication of other
viruses.141 Several studies have demonstrated that
IFNs are able to induce changes in the membrane
of cells, which may influence the adsorption and
penetration of cells by certain viruses.141 Other evi-
dence suggests that inhibition of virus replication
in macrophages by IFN-γ is mediated through pro-
duction of NO.35 The RNA-dependent protein ki-
nase, PKR, is believed to be a key component in the
control of protein synthesis in IFN-treated and
virus-infected cells. Induction of protein kinase
PKR by IFNs leads to phosphorylation of eukary-
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otic initiation factor 2α (eIF2α), which inhibits
protein synthesis and protects cells from virus in-
fection.142 Induction of a number of chemokines by
IFNs, such as Mig and IP-10/Crg-2, plays an im-
portant role in the inflammatory and healing
process during infection. On the other hand, IL-8
can inhibit the antiviral action of IFN-γ through
reduced 2′,5′-A oligoadenylate synthetase activi-
ty.143,144 There are many more proteins that can be
induced by IFNs and that can exert antiviral effects.
Several studies have shown that IFN-α and IFN-
β contributed to antiviral function in vivo. It was
demonstrated that administration of antibodies
against these factors to mice during infection with
HSV, MSV, VSV, Newcastle disease virus, EV, and
influenza virus increased the intensity and severity
of these infections, directly indicating a protective
role of these factors.145,146 Studies using mice that are
deficient in type I IFN receptor (IFN-α/β R GKO)
further support the importance of type I IFNs in
the early defense against virus infection.147 Despite
being armed with the capacity to mount an other-
wise normal immune response, the IFN-α/β R
GKO mice are highly susceptible to several viruses.
Tumor necrosis factors (TNFs)
TNF-α and TNF-β, now known as TNF and
lymphotoxin, respectively, have been reported to
have antiviral activity against a number of RNA
and DNA viruses in vitro, and this activity was
found to be dependent on endogenous IFN-
β.148,149 On the other hand, others have demonstrat-
ed that the antiviral activity of the TNFs is inde-
pendent of IFN-α, -β, and −γ. 150 TNF and
lymphotoxin act synergistically with the antiviral
activity of IFN-α, -β, and -γ on a variety of cell
types against a number of RNA and DNA viruses.
IFN-γ, a potent inhibitor of VV replication, also
synergizes with TNF. The importance of TNF in
recovery from viral infections has been demonstrat-
ed by the administration of recombinant TNF or
antibodies against TNF. For instance, recombinant
TNF inhibited the replication of encephalomy-
ocarditis virus (EMCV) and HSV.151,152 Although
the mechanism(s) are still not known, a recombi-
nant VV encoding TNF-α was found to be attenu-
ated in vivo by a mechanism that was neither de-
pendent on the induction of cell-mediated nor
humoral immunity.153
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Table 1 INTERFERON INDUCIBLE PROTEINS
PROTEINS CHARACTERISTICS INDUCER
2´5´ (A)n synthetase families 2´5´ (A)n synthesis α, β > γ
p68 kinase Protein phosphorylation α, β > γ
Indoleamine 2,3-dioygenase Tryptophan degradation γ > α, β
P56 Trp-tRNA synthetase γ > α, β
GBP/g67 Guanylate binding γ  > α, β
Mx families Anti-influenze virus α, β > γ
IRF-1 Transcription factor α, β, γ
IRF-2 Transcription factor α, β
MHC class I Immune system α, β, γ
MHC class II Immune system γ
β2-microglobulin Immune system α, β, γ
IP-10/Crg-2 Chemokine α, β, γ
Mig Chemokine γ
I-TAC Chemokine γ
IFN-β Cytokine γ
NOS2 NO synthase γ
Abbreviations: GBP = Guanylate binding protein; IRF = Interferon regulatory factor; MHC = Major histocompatibility complex; NOS2
Inducible isoform of nitric oxide synthase; IP = IFN-inducible protein; Crg = cytokine response gene; MIG = monokine induced by
IFN-; I-TAC = inteferon-inducible T cell alpha chemoattractant.
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Interleukin-12 (IL-12)
IL-12 is predominantly produced by
macrophages and monocytes. This heterodimeric
cytokine has a variety of effects on T lymphocytes
and NK cells. These include its ability to induce
IFN-γ secretion by T lymphocytes and NK cells, to
act as a growth factor for activated T lymphocytes
and NK cells, to enhance the lytic activity of NK
cells, and to facilitate specific CTL responses. IL-12
plays a unique role in regulating the balance be-
tween the type 1 and type 2 subsets of T helper
cells.119
Administration of recombinant IL-12 to mice re-
sults in protection against a number of viruses such
as VSV, EMCV, murine leukaemia virus (MuLV),
LCMV, and MCMV.154,155 Elevated levels of IL-12
heterodimer proteins are observed during MCMV
infection.10 Studies in IL-12 GKO mice established
the necessity for IL-12 to generate a T1 cytokine re-
sponse that is often required for elimination of in-
tracellular pathogens.156 Furthermore, studies have
shown that the antiviral activity of IL-12 is mediat-
ed through endogenous IFN-γ.157
In addition, IL-12 neutralization by antibody
treatment in mice infected with MCMV or EV re-
sulted in significantly higher virus titers recovered
from mice organs (Dr. G. Karupiah, JCSMR, per-
sonal communicationPROVIDE MONTH AND
YEAR).10
Interleukin-4 (IL-4)
IL-4 is an immunoregulatory cytokine produced
predominantly by Th2 cells. IL-4 is required for the
optimal development of this cell subset, while it in-
hibits the growth of Th1 cells. This cytokine is also
produced by mast cells and basophils. IL-4 is pro-
duced predominantly by T lymphocytes during
virus infections in vivo.
This cytokine blocks IL-2-dependent prolifera-
tion of T lymphocytes in vitro by down-regulating
IL-2 receptors.158 IL-4 can inhibit the production of
IFN-α and IFN-β, as well as blocking the capacity
of IFNs to protect cells from virus infection.159,160
IL-4 may also antagonize the actions of IL-12,
which is an important factor for the establishment
of type 1 responses.161 Treatment of mice with re-
combinant IL-4 delays clearance of HSV-1 and in-
fluenza virus.162,163 Recombinant VV encoding IL-4
exhibits enhanced virulence compared to a control
virus, and this is associated with decreased expres-
sion of type 1 cytokines, as well as decreased CTL
activity and NO production.164
Chemokines
Chemokines are low molecular weight chemoat-
tractant cytokines secreted by a variety of cells, in-
cluding leukocytes, epithelial cells, endothelial
cells, fibroblasts, and numerous other cell types.165
They are produced in response to exogenous stim-
uli such as viruses and bacterial LPS (lipopolysac-
charide), and endogenous stimuli such as IL-1,
TNF, and IFNs.166 These factors mediate chemo-
taxis and leukocyte activation. They also regulate
leukocyte extravasation from the blood and/or
lymph vessel luminal surface to the tissue space, the
site of inflammation. The release of chemokines
and the matrix upon or through which the cells tra-
verse governs the selective trafficking of leukocytes.
As well as playing this early role in host defense,
chemokines influence other leukocyte subsets, and
so influence the composition of a cellular infiltrate,
the outcome of infection, and the level of tissue
damage.
To date, more than 60 different chemokines have
been described (Table 2). A protein with 2 instead
of 4 conserved cysteines, lymphotactin (C
chemokine), and a chemokine-like structure with 3
amino acids between the 1st 2 cysteines (CX3C
chemokine) family containing a single member
each (fractalkine/neurotactin) has recently been
characterized.167,168 AUTHOR: PLEASE CLARIFY
THIS SENTENCE. ARE YOU IDENTIFYING
A PROTEIN FAMILY?
Chemokine receptors belong to the 7 transmem-
brane spanning family of G protein-coupled recep-
tors. Chemokines have 2 main sites of interaction
with their receptors, one in the N-terminal region
and the other within an exposed loop of the back-
bone that extends between the 2nd and 3rd cys-
teine.169 The N-terminal binding site is essential for
triggering of the receptor. The discovery of
chemokine receptors appears to be growing rapidly.
There are now 15 known chemokine receptors,
many of which exhibit multiple ligand specificity,
indicating that redundancy and versatility are char-
acteristic for the chemokine system.
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Table 2 CHEMOKINE NOMENCLATURE
SYSTEMATIC NAME LIGAND RECEPTOR
CC CHEMOKINE
CCL1 I-309 CCR8
CCl2 MCP-1 CCR2
CCL3 MIP-1α CCR1, CCR5
CCL4 MIP-1β CCR5
CCL5 RANTES CCR1, CCR3, CCR5
CCL7 MCP-3 CCR1, CCR2, CCR3
CCL8 MCP-2 CCR3
CCL11 Eotaxin CCR
CCL13 MCP-4 CCR2, CCR3
CCL14 HCC-1 CCR1
CC L15 MCC-2/Lkn-1/MIP-1γ
CCR1, CCR3
CCL16 HCC-4/LEC CCR1
CCL17 TARC CCR4
CCL18 DC-CK1 Not known
CCL19 NIP-3β/ELC/exodus-3 CCR7
CCL20 NIP-3α/LARC/exodus-1 CCR6
CCL21 6Ckine/SLC/exodus-2 CCR7
CCL2 MDC/STCP-1 CCR4
CCL23 MPIF-1 CCR1
CCL24 MPIF-2/Eotaxin-2 CCR3
CCL25 TECK CCR9
CCL26 Eotaxin-3 CCR3
CCL27 CTACK/ILC CCR10
CXC CHEMOKINE
CXCL1 GROα/MGSA-α CXCR2,CSCr1
CXCL2 GROβ/MGSA-β CXCR2
CXCL3 GROγ/MGSA-γ CXCR2
CXCL4 PF4 Not known
CXCL5 ENA78 CXCR2
CXCL6 GCP-2 CXCR1, CXCR2
CXCL7 NAP-2 CXCR2
CXCL8 IL-8 CXCR1, CXCR2
CXCL9 Mig CXCR3
CXCL10 IP-10 CXCR3
CXCL11 I-TAC CXCR3
CXCL12 SDF-1α/β CXCR4
CXCL13 BLC/BCA-1 CXCR5
CXCL14 BRAK/bolekine Not known
C CHEMOKINES
XCL1 Lymphotactin/SCM-1α XCR1
XCL2 SCM-1β SCR1
CX3C CHEMOKINE
CS3CL1 Fractalkine/neurotactin CX3CR1
REVIEWS
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Chemokines in Viral Infections
Chemokine Binding 
Proteins Encoded by Viruses
A number of viruses, particularly members of the
poxvirus, herpesvirus, and retrovirus families, have
adapted to the vertebrate immune responses by cap-
turing and modifying cellular genes that regulate
the host immune system (described below). Includ-
ed among these host-derived virus genes are modi-
fied versions of receptors and ligands for cytokines
and chemokines. The various cytokine receptor and
ligand homologs encoded by viruses are listed in
Table 3 and will not be discussed in this review.
Poxviruses
Poxvirus genomes encode several proteins that in-
hibit specific elements of the host immune system
including a secreted protein with high affinity
binding to virtually all known CC chemokines
(Table 4).170 The human cutaneous poxvirus, mol-
luscum contagiosum viruses (MCV) types 1 and 2,
contain chemokine-like genes that encode proteins
that are able to antagonize the chemotactic activity
of human chemokines.171 Myxoma virus M-T7 pro-
tein binds many CC, CXC, and C chemokines and
modulates the infiltration of leukocytes into infect-
ed tissues.172 Alcami and colleagues reported that a
soluble 35 kD protein encoded by VV strain Lister
has chemokine-binding activity,173 and similar pro-
teins are produced by 11 orthopoxviruses repre-
senting 3 species: VV, cowpox, and camelpox.170 It
was reported that the virus chemokine-binding
protein binds CC chemokines with high affinity
and inhibits their ability to induce signal transduc-
tion and cell migration in vitro.173
Herpesviruses
Human herpesvirus 8 (HHV-8), which is a Ka-
posi’s sarcoma-associated γ-herpesvirus (KSHV),
synthesizes several vCks, namely, vMIPI, vMIPII,
and vMIPIII. These molecules have similarity to
the CC chemokine, MIP-1α.174,175 vMIPII func-
tions as a competitive antagonist as it binds with
high affinity to both CC and CXC chemokine re-
ceptors and inhibits calcium mobilization upon
subsequent chemokine stimulation.176 vMIPI ap-
pears to be a selective agonist for CCR8, a receptor
that is expressed primarily on T cells of the T helper
2 (Th2) phenotype.177 HHV-8 also encodes a virus-
encoded chemokine receptor homolog, termed
ORF-74, which binds to a collection of CXC and
CC chemokines.178 ORF-74 activity is thought to
contribute to the formation of highly vascularized
tumors; however, the role of this molecule in this
process is yet to be fully elucidated. Interestingly,
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Table 3 ANTICYTOKINE STRATEGIES ENCODED BY VIRUSES
FUNCTION GENE/PROTEIN VIRUS MECHANISM
VTNFR M-T2 MV binds rabbit TNF
CrmB CPV binds rabbit TNF and LT-α
CrmC CPV, VV binds TNF
CrmD CPV, EV binds rabbit TNF and LT-α
CrmE CPV binds TNF
UL144 HCMV TMFR homolog
VIL-1βR B15R VV binds IL-1β
vIFN-γR M-T7, B8R MV, VV, CPV binds IFN-γ
vIFN-α/βR oBI8R VV binds type I IFNS
vCSF-1R BARF-1 EBV binds CSF-1
vGMCSF GIF OV binds GMCSF
vIL-18BP MC54 MCV binds IL-18
MC53 MCV binds IL-18
D7L EV, VV, CPV binds IL-18
VIL-10 BCRF-1 EBV IL-10 activity down-regulates Th1 response
Abbreviations: CPV = cowpox virus: MV = myxoma virus; EV = ectromeila virus; EBV = epstein barr virus; VV = vaccinia virus; MCV =
molluscum contagiosum virus.
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CXC chemokines CXCL10 and CXCL12 each in-
hibit signaling by ORF-74.179 This may have an im-
portant therapeutic application in inhibiting the ef-
fects of ORF-74.
Human cytomegalovirus (HCMV) is a species-re-
stricted β-herpesvirus. HCMV has been linked
with a variety of human syndromes, including
pneumonitis, obliterative bronchiolitis, and vascu-
lar injury-associated atherosclerosis.180,181 HCMV
infects epithelial, smooth muscle, and white blood
cells in vivo causing acute, latent, and chronic in-
fections. HCMV has long been known to possess
open reading frames (ORFs) encoding 7 trans-
membrane (7TM) proteins (US27, US28, UL33,
and UL78).182 The HCMV chemokine receptor ho-
molog US28 induces second-messenger signaling,
including calcium flux in response to the CC
chemokines CCL2, CCL3, CCL4, and CCL5.183
Thus, HCMV can alter the chemokine environ-
ment of infected cells through strong sequestering
of CC chemokines, mediated principally by expres-
sion of the US28-encoded chemokine receptor.
Therefore, US28 binding to chemokines inhibits
both leukocyte chemotaxis and activation of effec-
tor function.
Human Cytomegalovirus (HCMV) Infection
Virus-induced alterations in the cellular expres-
sion of chemokines may be important in directing
the migration of specific leukocyte subsets to sites
of infection, thereby playing a pivotal role in viral
pathogenesis. For instance, HCMV infection of
human fibroblasts resulted in significantly in-
creased expression of IL-8.184 The increase in IL-8
production has functional consequences, as
demonstrated by the ability of supernatants from
HCMV-infected fibroblasts to significantly en-
hance neutrophil transendothelial migration. Neu-
trophils play an important role in the dissemina-
tion of HCMV throughout the body, and thus
HCMV-induced neutrophil recruitment would be
expected to enhance HCMV dissemination.
Human Immunodeficiency Virus (HIV) Infection
The CC-chemokines RANTES, MIP-1α, and
MIP-1β have now been identified as soluble sup-
pressors of macrophage-tropic, but not T lympho-
cyte cell line-tropic, HIV infection in vitro.98 The
molecular mechanism of HIV suppressor activity
by chemokines has been revealed to occur at the
level of chemokine receptors. The orphan
chemokine receptor, designated fusin, is the co-re-
ceptor for fusion and entry of the T lymphocyte
cell line-tropic form of HIV-1.185 This receptor al-
lowed for entry of T lymphocyte cell line-tropic
form of HIV-1, but was not permissive for
macrophage-tropic isolates. Subsequent studies
have shown that fusin is a receptor for the CXC
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Table 4 ANTICHEMOKINE STRATEGIES ENCODED BY VIRUSES
Membrane Chemokine Receptor-like Protein
Swinepox K2R
Sheepox Q2/3l
Murine CMV M33
Human CMV US27, US28, UL-33
Herpesvirus Salmiri ECRF-3
KSHV ORF-74
Chemokien Homologue
Molluscum contagiosum MC1 48R
KSHV K4, K6
Human herpesvirus-6 U83, DR1, DR6
Soluble Binding Protein
Vaccinia B29R, 35 kDa, CKBP
Myxoma M-T7, M-T1
Various Orthopoxviruses 35kDa CKBP
Abbreviations: KSHV = Kaposi’s Sarcoma herpesvirus; CKBP = chemokine binding protein.
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chemokine SDF-1, hence its even more recent re-
designation as CXCR4.186 The co-receptor for
macrophage-tropic HIV-1 has also been identi-
fied.187,188 Here the chemokine receptors CCR5 and,
for some HIV-1 strains, CCR3 are implicated.
CCR5 has as its ligands RANTES, MIP-1α, and
MIP-1β, the same chemokines that act as in-
hibitors of macrophage-tropic HIV-1.98 Recent ge-
netic evidence suggests that individuals homozy-
gous for a CCR5 deletion mutant are resistant to
HIV infection.189
Interferon-Inducible Chemokines 
in the Control of VV Infection
As described earlier, IFNs have been shown to
play an important role in the control of poxvirus
replication by mediating antiviral activity through
the induction of several other proteins such as IP-
10 and Mig. Both Mig and IP-10 are chemoattrac-
tant for NK cells and T lymphocytes. The delivery
of cytokines using recombinant VV (rVV) has
proved a favorable model for establishing their an-
tiviral/biological activity in vivo, and such a strate-
gy has been used to express a number of type 1 and
type 2 cytokines. Using this expression system, IP-
10 and Mig have been shown to exhibit antiviral
activity in vivo.190 In infected mice, rVV-encoded
IP-10 or Mig enhanced the cytolytic activity of NK
cells, mononuclear cell infiltration in livers, and
IFN secretion by 2 to 3 times and resulted in sig-
nificant viral clearance and survival in nude mice.
In contrast, mice infected with a control virus
(rVV-X) that does not express chemokines suc-
cumbed to generalized infection and died.
Chemokine to Cytokine to Chemokine Cascade 
in the Control of MCMV Infection
In humans, the liver is a common target organ of
CMV infections. Similarly, MCMV can infect the
liver and cause profound disease in mice. MIP-1α
triggers NK cell inflammation in the liver during
MCMV infections, and IFN-γ produced by NK
REVIEWS
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Figure 1. A model of chemokine function during a murine cytomegalovirus (MCMV) infection. During viral infection, chemokines
perform two functions; the first is the recruitment of effector cells to the site of infection and the second is the activation of those
effector cells. These activated cells can trigger the killing of virally infected cells through cytolytic activity, as well as a capacity to
produce IFNs leading to a variety of anti-viral mechanisms as well as a secondary wave of chemokine release which recruit yet
more effector cells.
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cells contributes to defense against MCMV infec-
tions.191 THERE IS NO REF NO. 191MIP-1α
deficiency profoundly decreases resistance to
MCMV and is associated with dramatically re-
duced NK cell accumulation and IFN-γ produc-
tion in the liver. MIP-1α-independent IFN-γ re-
sponses have been observed in serum and spleen,
and infection-induced elevations in blood NK cell
populations occur in absence of MIP-1α. Peak liv-
er expression of Mig, however, depends upon the
presence of MIP-1α, NK cells, and IFN-γ. The
Mig response is also important for viral resistance.
Therefore, MIP-1α is critical for NK cell migration
and IFN-γ delivery to mediate protection; thus,
Mig induction in tissues is a downstream protective
response resulting from the process (Fig. 1).
Conclusion
In just a few years, there has been enormous un-
derstanding of what chemokines are and what they
do in a number of functional settings. It is also clear
that their role is not restricted just to cell attraction.
As the specifics of chemokine biology become clear,
this information should prove applicable to the de-
sign of therapies for a variety of autoimmune, in-
flammatory, and infectious disorders. The genera-
tion and use of transgenic and GKO mouse models
of chemokines and/or chemokine receptor(s)
should ultimately prove essential tools for filling
the gaps in our knowledge on the precise function-
al importance of individual chemokines in modu-
lating the immune response. One would only hope
that as the discovery of more chemokines and their
receptors continues rapidly, their understanding
and functional relevance continue to progress at a
comparable rate.
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